Join the club for FREE to access the whole archive and other member benefits.

New drugs lack proof of added benefit over existing drugs

Old drugs are just as good as those new drugs - pharmaceutical mafia in action

10-Jul-2019

Key points from article :

Many new drugs entering the German healthcare system have not been shown to add benefit.

Assessed 216 drugs entering the German market following regulatory approval from 2011 to 2017.

125 drugs (58%) did not have a proven added benefit over standard care.

Only 54 drugs (25%) showed a considerable or major added benefit.

Regulatory authorities should demand robust evidence to prove efficacy and safety of drugs.

Must revise the legal and regulatory framework and introduce new drug development models.

Study by Institute for Quality and Efficiency in Health Care, Cologne, Germany published in British Medical Journal.

Mentioned in this article:

Click on resource name for more details.

Beate Wieseler

Head of IQWiG's Drug Assessment Department.

Institute for Quality and Efficiency in Health Care (IQWiG)

German agency responsible for assessing the quality and efficiency of medical treatments

The BMJ

Publisher of more than 70 medical and allied science journals

Topics mentioned on this page:
Big Pharma